Literature DB >> 16219294

High level production of secreted proteins: example of the human tissue inhibitor of metalloproteinases 1.

L Crombez1, B Marques, J L Lenormand, N Mouz, B Polack, C Trocme, B Toussaint.   

Abstract

The major difficulty for high-throughput screening of therapeutic protein candidates in experimental animal models of pathologies or for structural studies is their fast and efficient production. The tissue inhibitors of metalloproteinases (TIMPs) considered to play a role in many physiological and pathological processes, such as arthritis or cancer, by inhibiting matrix metalloproteinases or acting as signalling molecules, have always been produced with huge difficulties. We hereby propose a new method to overproduce human recombinant TIMP-1 by transient expression in HEK293E cells, followed by a one-step chromatography purification, yielding in only 2 weeks, dozens of milligrams of pure, stable, glycosylated and active protein for in vitro and in vivo studies. This easy to set up, rapid, and efficient method could be applied for any naturally secreted mammalian protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219294     DOI: 10.1016/j.bbrc.2005.09.136

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.

Authors:  Jyotica Batra; Jessica Robinson; Alexei S Soares; Alan P Fields; Derek C Radisky; Evette S Radisky
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

2.  Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.

Authors:  Maryam Raeeszadeh-Sarmazdeh; Kerrie A Greene; Banumathi Sankaran; Gregory P Downey; Derek C Radisky; Evette S Radisky
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

3.  Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Authors:  Christine Mehner; Ann L Oberg; Kimberly R Kalli; Aziza Nassar; Alexandra Hockla; Devon Pendlebury; Magdalena A Cichon; Krista M Goergen; Matthew J Maurer; Ellen L Goode; Gary L Keeney; Aminah Jatoi; Miklós Sahin-Tóth; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Oncotarget       Date:  2015-11-03

4.  PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1).

Authors:  Jyotica Batra; Jessica Robinson; Christine Mehner; Alexandra Hockla; Erin Miller; Derek C Radisky; Evette S Radisky
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.